FindTrial
Sign In

Study on the pathogenesis, diagnosis, treatment and strategy of Brucellosis

Study on new diagnostic methods and treatment strategies of Brucellosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17014016
Enrollment
Unknown
Registered
2017-12-18
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis

Interventions

Gold Standard:agglutination test
Index test:ELISPOT method

Sponsors

First Affliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Brucellosis patients diagnose with People's Republic of China health industry standard WS269-2007 brucellosis diagnostic standard

Exclusion criteria

Exclusion criteria: 1. Complication with severe organ dysfunction, such as heart failure, liver and kidney failure, etc. 2. Drug allergy 3. Not willing to participate in this test

Design outcomes

Primary

MeasureTime frame
SPE, SEN, ACC, AUC and ROC;—

Countries

China

Contacts

Public ContactYongguo Li
liyongguodoctor@163.com+86 13904505981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026